Hepatitis C virus genetic variability in 52 human immunodeficiency virus-coinfected patients

Journal of Medical Virology

Volumn 71, Issue 1, 2003, Pages 41-48

  Neau, Didier ^a,b   Jouvencel, Anne Christine ^a   Legrand, Elisabeth ^a   Trimoulet, Pascale ^a   Galperine, Tatiana ^a,b   Chitty, Isabelle ^a   Ventura, Michel ^a   Le Bail, Brigitte ^a   Morlat, Philippe ^c   Lacut, Jean Yves ^b   Ragnaud, Jean Marie ^b   Dupon, Michel ^b   Fleury, Hervé ^a   Lafon, Marie Edith ^a  

^a UNIVERSITÉ DE BORDEAUX   (France)

^b HÔPITAL PELLEGRIN   (France)

^c HÔPITAL SAINT ANDRÉ   (France)

Author keywords

Anti HCV treatment; HCV variability; HIV HCV coinfection; Predictive factors; SSCP

Indexed keywords

PROTEINASE INHIBITOR; RECOMBINANT ALPHA2A INTERFERON; RIBAVIRIN;

ADULT; ARTICLE; CHRONIC HEPATITIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG RESPONSE; FEMALE; GENETIC VARIABILITY; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; PREDICTION; RANDOMIZED CONTROLLED TRIAL; SINGLE STRAND CONFORMATION POLYMORPHISM; SUPERINFECTION; VIRUS LOAD;

ADOLESCENT; ADULT; AIDS-RELATED OPPORTUNISTIC INFECTIONS; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL; VARIATION (GENETICS);

HEPATITIS C VIRUS; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 0141459378     PISSN: 01466615     EISSN: None     Source Type: Journal    
DOI: 10.1002/jmv.10451     Document Type: Article

References (36)

1. Bedossa P, Poynard T, for the METAVIR Cooperative Study Group. 1996. An algorithm for the grading of activity in chronic hepatitis C. Hepatology 24:289-293.
2. Booth JCL, Kumar U, Webster D, Monjardino J, Thomas HC. 1998. Comparison of the rate of sequence variation in the hypervariable region of E2/NS1 region of hepatitis C virus in normal and hypogammaglobulinemic patients. Hepatology 26:223-227.
3. Cacoub P, Geffray L, Rosenthal E, Perrone C, Veyssier P, Raguin G. 2001. Mortality among HIV-infected patients with cirrhosis or hepatocarcinoma due to hepatitis C virus in French departments of internal medicine/infectious diseases in 1995 and 1997. Clin Infect Dis 32:1207-1214.
4. Cribier B, Rey D, Schmitt C, Lang JM, Kirn A, Stoll-Keller F. 1995. High hepatitis C viraemia and impaired antibody response in patients coinfected with HIV. AIDS 9:1131-1136.
5. Davis GL, Lau JYN, Urdea MS, Neuwald P, Wilber JC, Lindsay K, Perrillo RP, Albrecht J. 1994. Quantitative detection of hepatitis C virus RNA by solid phase branched DNA amplification method: definition and optimal conditions for specimen collection and clinical application in interferon-treated patients. Hepatology 19:1337-1341.
6. Dorruci M, Pezzotti P, Philips AN, Lepri AC, Rezza G. 1995. Coinfection of hepatitis C virus with human immunodeficiency virus. J Infect Dis 172:1503-1508.
7. Enomoto N, Kurosaki M, Tanaka Y, Marumo F, Sato C. 1994. Fluctuation of hepatitis C virus quasispecies in persistent infection and interferon treatment revealed by single-strand conformation polymorphism analysis. J Gen Virol 75:1361-1369.
8. Farci P, Purcell RH. 2000. Clinical significance of hepatitis C virus genotypes and quasispecies. Semin Liver Dis 20:103-126.
9. Farci P, Shimoda A, Coiana A, Diaz G, Peddis G, Melpolder JC, Strazzera A, Chien DY, Munoz SJ, Balestrieri A, Purcell RH, Alter HJ. 2000. The outcome of acute hepatitis C predicted by the evolution of the viral quasispecies. Science 288:339-344.
10. Farci P, Strazzera R, Alter HJ, Farci S, Degioannis D, Coiana A, Peddis G, Usai F, Serra G, Chessa L, Diaz G, Balestrieri A, Purcell RH. 2002. Early changes in hepatitis C viral quasispecies during interferon therapy predict the therapeutic outcome. Proc Natl Acad Sci USA 99:3081-3086.
11. Frangeul L, Cresta P, Perrin M, Lunel F, Opolon P, Agut H, Huraux JM. 1998. Mutations in NS5A region of hepatitis C virus genome correlate with presence of NS5A antibodies and response to interferon therapy in most common European hepatitis C virus genotypes. Hepatology 28:1674-1679.
12. Gonzalez-Peralta RP, Qian K, She JY, Davis GL, Ohno T, Mizokami M, Lau JYN. 1996. Clinical implications of viral quasispecies heterogeneity in chronic hepatitis C. J Med Virol 49:242-247.
13. Gonzalez-Peralta RP, Liu WZ, Davis GL, Qian KP, Lau JY. 1997. Modulation of hepatitis C virus quasispecies heterogeneity by interferon-alpha and ribavirin therapy. J Viral Hepatol 4:99-106.
14. Gretch DR, Polyak SJ. 1997. The quasispecies nature of hepatitis C virus: research methods and biological implications. In: Groupe Français d'Etudes Moléculaires des Hépatites (GEMHEP) editors. Hepatitis C virus: genetic heterogeneity and viral load. Paris: John Libbey Eurotext. p 57-69.
15. Hoggard P, Kewn S, Barry MG, Khoo SH, Back DJ. 1997. Effects of drugs on 2′,3′-dideoxy-2′,3′-didehydrothymidine phosphorylation in vitro. Antimicrob Agents Chemother 41:1231-1236.
16. Le Guen B, Squadrito G, Nalpas B, Berthelot P, Pol S, Brechot C. 1997. Hepatitis C virus genome complexity correlates with response to interferon therapy: a study in French patients with chronic hepatitis C. Hepatology 25:1250-1254.
17. Lopez-Labrador FX, Ampurdanes S, Gimenez-Barcons M, Guilera M, Costa J, Jimenez de Anta MT, Sanchez-Tapias JM, Rodes J, Saiz JC. 1999. Relationship of the genomic complexity of hepatitis C virus with liver disease severity and response to interferon in patients with chronic HCV genotype 1b infection. Hepatology 29:897-903.
18. Neumann AU, Lam NP, Dahari H, Gretch DR, Wiley TE, Layden TJ, Perelson AS. 1998. Hepatitis C viral dynamics and the antiviral efficacy of interferon-α therapy. Science 282:103-107.
19. Ni YH, Chang MH, Chen PJ, Hsu HY, Lu TW, Lin KH, Lin DT. 1999. Decreased diversity of hepatitis C virus quasispecies during bone marrow transplantation. J Med Virol 58:132-138.
20. Pawlotsky JM, Pellerin M, Bouvier M, Roudot-Thoraval F, Germanidis G, Bastie A, Darthuy F, Rémiré J, Soussy CJ, Dhumeaux D. 1998. Genetic complexity of the hypervariable region 1 (HVR1) of hepatitis C virus (HCV): influence on the characteristics of the infection and responses to interferon alpha therapy in patients with chronic hepatitis C. J Med Virol 54:256-264.
21. Pawlotsky JM, Germanidis G, Frainais PO, Bouvier M, Soulier A, Pellerin M, Dhumeaux D. 1999. Evolution of the hepatitis C virus second envelope protein hypervariable region in chronically infected patients receiving alpha interferon therapy. J Virol 73:6490-6499.
22. Piroth L, Duong M, Quantin M, Abrahamowicz M, Michardière R, Aho LS, Grappin M, Buisson M, Waldner A, Portier H, Chavanet P. 1998. Does hepatitis C virus (HCV) co-infection accelerate clinical and biological evolution of HIV-infected patients ? AIDS 12:381-388.
23. Pontesilli O, Carotenuto P, Kerkhof-Garde SR, Roos MTM, Keet IPM, Coutinho RA, Goudsmit J, Miedema F. 1999. Lymphoproliferative response to HIV type 1 p24 in long-term survivors of HIV type 1 infection is predictive of persistent AIDS-free infection. AIDS Res Hum Retroviruses 15:973-981.
24. Roque-Afonso AM, Robain M, Simoneau D, Rodriguez-Mathieu P, Gigou M, Meyer L, Dussaix E. 2002. Influence of CD4 counts on the genetic heterogeneity of hepatitis C virus in patients coinfected with human immunodeficiency virus. J Infect Dis 185:728-733.
25. Saillour F, Dabis F, Dupon M, Lacoste D, Trimoulet P, Rispal P, Monlun E, Ragnaud JM, Morlat P, Pellegrin JL, Fleury H, Couzigou P. 1996. Prevalence and determinants of antibodies to hepatitis C virus and markers for hepatitis B virus infection in patients with HIV infection in Aquitaine. BMJ 313:461-464.
26. Sandres K, Dubois M, Pasquier C, Payen JL, Alric L, Duffaut M, Vinel JP, Pascal JP, Puel J, Izopet J. 2000. Genetic heterogeneity of hypervariable region 1 of the hepatitis C virus (HCV) genome and sensitivity of HCV to alpha interferon therapy. J Virol 74:661-668.
27. Sherman KE, O'Brien J, Gutierrez AG, Harrison S, Urdea M, Neuwald P, Wilber J. 1993. Quantitative evaluation of hepatitis C virus RNA in patients with concurrent human immunodeficiency virus infections. J Clin Microbiol 31:2679-2682.
28. Sherman KE, Andreatta C, O'Brien J, Guttierrez A, Harris R. 1996. Hepatitis C in human immunodeficiency virus-coinfected patients: increased variability in the hypervariable envelope coding domain. Hepatology 23:688-694.
29. Soriano V, Garcia-Samaniego J, Valencia E, Rodriguez-Rosado R, Munoz F, Gonzales-Lahoz J. 1999a. Impact of chronic liver disease due to hepatitis viruses as cause of hospital admission and death in HIV-infected drug users. Eur J Epidemiol 15:1-4.
30. Soriano V, Rodriguez-Rosado R, Garcia-Samaniego J. 1999b. Management of chronic hepatitis C in HIV-infected patients. AIDS 13:539-546.
31. Spengler U, Rockstroh JK. 1998. Hepatitis C in the patients with human immunodeficiency virus infection. J Hepatol 29:1023-1030.
32. Takaki A, Wiese M, Maertens G, Depla E, Seifert U, Liebetrau A, Miller JL, Manns MP, Rehermann B. 2000. Cellular immune responses persist and humoral responses decrease two decades after recovery from a single source outbreak of hepatitis C. Nature Med 6:578-582.
33. Thomas DL, Shih JW, Alter HJ, Vlahov D, Cohn S, Hoover DR, Cheung L, Nelson KE. 1996. Effect of human immunodeficiency virus on hepatitis C virus infection among injecting drug users. J Infect Dis 174:690-695.
34. Thomas DL, Astemborski J, Vlahov D, Strathdee SA, Ray SC, Nelson KE, Galai N, Nolt KR, Laeyendecker O, Todd JA. 2000. Determinants of the quantity of hepatitis C virus RNA. J Infect Dis 181:844-851.
35. Toyoda H, Fukuda Y, Koyama Y, Takamatsu J, Saito H, Hayakawa T. 1997. Effect of immunosuppression on composition of quasispecies population of hepatitis C virus in patients with chronic hepatitis C coinfected with human immunodeficiency virus. J Hepatol 26:975-982.
36. Vogt MW, Hartshorn KL, Furman PA, Chou TC, Fyfe JA, Coleman LA, Crumpacker C, Schooley RT, Hirsch MS. 1987. Ribavirin antagonizes the effect of azidothymidine on HIV replication. Science 235:1376-1379.